• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Clinical immunology: The official journal of the Clinical Immunology Society >Syk inhibition with fostamatinib leads to transitional B lymphocyte depletion
【24h】

Syk inhibition with fostamatinib leads to transitional B lymphocyte depletion

机译：Fostamatinib抑制Syk会导致过渡性B淋巴细胞耗竭

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Cell signaling initiated by the B cell receptor is critical to normal development of B lymphocytes, most notably at the transitional B cell stage. Inhibition of this signaling pathway with the syk inhibitor, fostamatinib, has produced significant efficacy in lymphoid malignancies and autoimmune conditions. Here, we demonstrate that short-term use of fostamatinib impairs B lymphocyte development at the transitional stage without affecting mature B cell populations. Additionally, IL-10 producing B cells remained relatively constant throughout the treatment period. These findings provide insight into the mechanism of action of B cell receptor inhibition in autoimmune disease. As the development of agents targeting B cell receptor signaling proceeds, monitoring for long-term consequences as well as functional evaluation of B cell subsets may further improve our understanding of this rapidly growing class of novel agents.
机译：由B细胞受体启动的细胞信号转导对于B淋巴细胞的正常发育至关重要，特别是在过渡性B细胞阶段。 syk抑制剂fostamatinib对这种信号通路的抑制作用在淋巴恶性肿瘤和自身免疫性疾病中产生了显着的疗效。在这里，我们证明了在过渡阶段短期使用fostamatinib会损害B淋巴细胞的发育，而不会影响成熟的B细胞群体。另外，在整个治疗期间，产生IL-10的B细胞保持相对恒定。这些发现提供了对自身免疫性疾病中B细胞受体抑制作用机制的见解。随着靶向B细胞受体信号转导的药物的发展，对B细胞亚群的长期后果以及功能评估的监测可能会进一步增进我们对这种迅速增长的新型药物的了解。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号